The elevated aldosterone in primary aldosteronism (PA) is associated with increased insulin resistance and prevalence of diabetes mellitus (DM). Both aldosterone excess and DM lead to left ventricular (LV) pathological remodeling. In this study, we investigated the impact of DM on LV non-hemodynamic remodeling in patients with PA. We enrolled 665 PA patients, of whom 112 had DM and 553 did not. Clinical, biochemical, and echocardiographic data were analyzed at baseline and 1 year after adrenalectomy. LV non-hemodynamic remodeling was represented by inappropriate excess left ventricular mass index (ieLVMI), which was defined as the difference between left ventricular mass index (LVMI) and predicted left ventricular mass index (pLVMI). Propensity score matching (PSM) was used with age, sex, systolic, and diastolic blood pressure to adjust for baseline variables. After PSM, the patient characteristics were balanced between the DM and non-DM groups, except for fasting glucose, HbA1c, and lipid profile. A total of 111 DM and 419 non-DM patients were selected for further analysis. Compared to the non-DM group, the DM group had significantly higher ieLVMI and LVMI. After multivariable linear regression analysis, the presence of DM remained a significant predictor of increased ieLVMI. After adrenalectomy, ieLVMI decreased significantly in the non-DM group but not in DM group. The presence of DM in PA patients was associated with more prominent non-hemodynamic LV remodeling and less recovery after adrenalectomy.
ReinckeMFischerEGerumS, et al. Observational study mortality in treated primary aldosteronism: the German Conn’s registry. Hypertension2012; 60: 618–624.
2.
SavardSAmarLPlouinPF, et al. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension2013; 62: 331–336.
3.
MulateroPMonticoneSBertelloC, et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab2013; 98: 4826–4833.
4.
CatenaCColussiGNadaliniE, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med2008; 168: 80–85.
5.
MilliezPGirerdXPlouinPF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol2005; 45: 1243–1248.
6.
FunderJWCareyRMManteroF, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab2016; 101: 1889–1916.
7.
HannemannAWallaschofskiH.Prevalence of primary aldosteronism in patient’s cohorts and in population-based studies–a review of the current literature. Horm Metab Res2012; 44: 157–162.
8.
XuZYangJHuJ, et al. Primary aldosteronism in patients in China with recently detected hypertension. J Am Coll Cardiol2020; 75: 1913–1922.
9.
HundemerGLCurhanGCYozampN, et al. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol2018; 6: 51–59.
10.
JosephJJEchouffo-TcheuguiJBKalyaniRR, et al. Aldosterone, renin, and diabetes mellitus in African Americans: the Jackson heart study. J Clin Endocrinol Metab2016; 101: 1770–1778.
11.
HanslikGWallaschofskiHDietzA, et al. Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn’s Registry. Eur J Endocrinol2015; 173: 665–675.
12.
AdlerGKMurrayGRTurcuAF, et al. Primary aldosteronism decreases insulin secretion and increases insulin clearance in humans. Hypertension2020; 75: 1251–1259.
13.
IngelssonEPencinaMJToflerGH, et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham offspring study. Circulation2007; 116: 984–992.
14.
WrightAKKontopantelisEEmsleyR, et al. Cardiovascular risk and risk factor management in type 2 diabetes mellitus. Circulation2019; 139: 2742–2753.
15.
EinarsonTRAcsALudwigC, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol2018; 17: 83.
16.
TancrediMRosengrenASvenssonAM, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med2015; 373: 1720–1732.
17.
RossiGPSechiLAGiacchettiG, et al. Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol Metab2008; 19: 88–90.
18.
TsaiCHWuXMLiaoCW, et al. Diabetes mellitus is associated with worse baseline and less post-treatment recovery of arterial stiffness in patients with primary aldosteronism. Ther Adv Chronic Dis2022; 13: 20406223211066727.
19.
KozakovaMBuralliSPalomboC, et al. Myocardial ultrasonic backscatter in hypertension: relation to aldosterone and endothelin. Hypertension2003; 41: 230–236.
20.
RossiGPDi BelloVGanzaroliC, et al. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension2002; 40: 23–27.
21.
TanabeANaruseMNaruseK, et al. Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension. Hypertens Res1997; 20: 85–90.
22.
RossiGPSacchettoAPavanE, et al. Remodeling of the left ventricle in primary aldosteronism due to Conn’s adenoma. Circulation1997; 95: 1471–1478.
23.
RossiGPSacchettoAVisentinP, et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension1996; 27: 1039–1045.
24.
GonzalezARavassaSLopezB, et al. Myocardial remodeling in hypertension. Hypertension2018; 72: 549–558.
25.
VerdecchiaPCariniGCircoA, et al. Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol2001; 38: 1829–1835.
26.
NadruzW.Myocardial remodeling in hypertension. J Hum Hypertens2015; 29: 1–6.
27.
AnsteyDETannerRMBoothJN3rd, et al. Inappropriate left ventricular mass and cardiovascular disease events and mortality in blacks: the Jackson heart study. J Am Heart Assoc2019; 8: e011897.
28.
de SimoneGDevereuxRBKimballTR, et al. Interaction between body size and cardiac workload: influence on left ventricular mass during body growth and adulthood. Hypertension1998; 31: 1077–1082.
29.
HungCSHoYLChangYY, et al. Twenty-four-hour urinary aldosterone predicts inappropriate left ventricular mass index in patients with primary aldosteronism. Sci World J2013; 2013: 294594.
30.
RossiGPCesariMCuspidiC, et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension2013; 62: 62–69.
31.
HungCSChouCHWuXM, et al. Circulating tissue inhibitor of matrix metalloproteinase-1 is associated with aldosterone-induced diastolic dysfunction. J Hypertens2015; 33: 1922–1930; discussion 1930.
32.
ChangYYTsaiCHPengSY, et al. KCNJ5 somatic mutations in aldosterone-producing adenoma are associated with a worse baseline status and better recovery of left ventricular remodeling and diastolic function. Hypertension2021; 77: 114–125.
33.
CioffiGFaggianoPLucciD, et al. Inappropriately high left ventricular mass in patients with type 2 diabetes mellitus and no overt cardiac disease. The DYDA study. J Hypertens2011; 29: 1994–2003.
34.
KozakovaMMorizzoCFraserAG, et al. Impact of glycemic control on aortic stiffness, left ventricular mass and diastolic longitudinal function in type 2 diabetes mellitus. Cardiovasc Diabetol2017; 16: 78.
35.
SeferovicJPTesicMSeferovicPM, et al. Increased left ventricular mass index is present in patients with type 2 diabetes without ischemic heart disease. Sci Rep2018; 8: 926.
36.
ChirinosJABhattacharyaPKumarA, et al. Impact of diabetes mellitus on ventricular structure, arterial stiffness, and pulsatile hemodynamics in heart failure with preserved ejection fraction. J Am Heart Assoc2019; 8: e011457.
37.
CosentinoFGrantPJAboyansV, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J2020; 41: 255–323.
38.
WuVCHuYHErLK, et al. Case detection and diagnosis of primary aldosteronism-The consensus of Taiwan society of aldosteronism. J Formos Med Assoc2017; 116: 993–1005.
39.
TsaiCHLiaoCWWuXM, et al. Autonomous cortisol secretion is associated with worse arterial stiffness and vascular fibrosis in primary aldosteronism: a cross-sectional study with follow-up data. Eur J Endocrinol2022; 187: 197–208.
40.
NaguehSFAppletonCPGillebertTC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr2009; 22: 107–133.
41.
SahnDJDeMariaAKissloJ, et al. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation1978; 58: 1072–1083.
42.
DevereuxRBAlonsoDRLutasEM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol1986; 57: 450–458.
43.
FrustaciALetiziaCVerardoR, et al. Primary aldosteronism-associated cardiomyopathy: clinical-pathologic impact of aldosterone normalization. Int J Cardiol2019; 292: 141–147.
44.
GrytaasMASellevagKThordarsonHB, et al. Cardiac magnetic resonance imaging of myocardial mass and fibrosis in primary aldosteronism. Endocr Connect2018; 7: 413–424.
45.
ChouCHHungCSLiaoCW, et al. IL-6 trans-signalling contributes to aldosterone-induced cardiac fibrosis. Cardiovasc Res2018; 114: 690–702.
46.
LiaoCWLinYTWuXM, et al. The relation among aldosterone, galectin-3, and myocardial fibrosis: a prospective clinical pilot follow-up study. J Investig Med2016; 64: 1109–1113.
47.
TsaiCHPanCTChangYY, et al. Left ventricular remodeling and dysfunction in primary aldosteronism. J Hum Hypertens2021; 35: 131–147.
Lopez-AndresNMartin-FernandezBRossignolP, et al. A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone. Am J Physiol Heart Circ Physiol2011; 301: H2372–H2382.
50.
LopezNDiezJFortunoMA.Differential hypertrophic effects of cardiotrophin-1 on adult cardiomyocytes from normotensive and spontaneously hypertensive rats. J Mol Cell Cardiol2006; 41: 902–913.
51.
HungCSChouCHLiaoCW, et al. Aldosterone induces tissue inhibitor of metalloproteinases-1 expression and further contributes to collagen accumulation: from clinical to bench studies. Hypertension2016; 67: 1309–1320.
52.
RudeMKDuhaneyTAKusterGM, et al. Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes. Hypertension2005; 46: 555–561.
53.
SomannaNKYariswamyMGaraglianoJM, et al. Aldosterone-induced cardiomyocyte growth, and fibroblast migration and proliferation are mediated by TRAF3IP2. Cell Signal2015; 27: 1928–1938.
54.
BrillaCGZhouGMatsubaraL, et al. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol1994; 26: 809–820.
55.
ColussiGCatenaCLapennaR, et al. Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care2007; 30: 2349–2354.
56.
CatenaCLapennaRBaroselliS, et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab2006; 91: 3457–3463.
57.
MossoLMCarvajalCAMaizA, et al. A possible association between primary aldosteronism and a lower beta-cell function. J Hypertens2007; 25: 2125–2130.
58.
ReinckeMMeisingerCHolleR, et al. Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn’s registry. Horm Metab Res2010; 42: 435–439.
59.
MatrozovaJSteichenOAmarL, et al. Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study. Hypertension2009; 53: 605–610.
60.
RemdeHHanslikGRayesN, et al. Glucose metabolism in primary aldosteronism. Horm Metab Res2015; 47: 987–993.
61.
EguchiKBoden-AlbalaBJinZ, et al. Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population. Am J Cardiol2008; 101: 1787–1791.
62.
HeckbertSRPostWPearsonGD, et al. Traditional cardiovascular risk factors in relation to left ventricular mass, volume, and systolic function by cardiac magnetic resonance imaging: the multiethnic study of atherosclerosis. J Am Coll Cardiol2006; 48: 2285–2292.
63.
PierdomenicoSDCuccurulloF.Risk reduction after regression of echocardiographic left ventricular hypertrophy in hypertension: a meta-analysis. Am J Hypertens2010; 23: 876–881.
64.
DevereuxRBDahlofBGerdtsE, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan intervention for endpoint reduction in hypertension (LIFE) trial. Circulation2004; 110: 1456–1462.
65.
GargPAssadiHJonesR, et al. Left ventricular fibrosis and hypertrophy are associated with mortality in heart failure with preserved ejection fraction. Sci Rep2021; 11: 617.
66.
UrzuaFresno CMFoladorLShalmonT, et al. Prognostic value of cardiovascular magnetic resonance left ventricular volumetry and geometry in patients receiving an implantable cardioverter defibrillator. J Cardiovasc Magn Reson2021; 23: 72.
67.
NaingZQiuCG.Dawn of the most influential mechanism from the nightmare of slow coronary flow phenomenon: a randomized controlled study. Int J Cardiol2013; 168: 4951–4953.
68.
KupersteinRHanlyPNiroumandM, et al. The importance of age and obesity on the relation between diabetes and left ventricular mass. J Am Coll Cardiol2001; 37: 1957–1962.
69.
PhillipsRAKrakoffLRDunaifA, et al. Relation among left ventricular mass, insulin resistance, and blood pressure in nonobese subjects. J Clin Endocrinol Metab1998; 83: 4284–4288.
70.
HillDJMilnerRD.Insulin as a growth factor. Pediatr Res1985; 19: 879–886.
71.
StrausDS.Growth-stimulatory actions of insulin in vitro and in vivo. Endocr Rev1984; 5: 356–369.
72.
ItoHHiroeMHirataY, et al. Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation1993; 87: 1715–1721.
73.
PaulusWJDal CantoE.Distinct myocardial targets for diabetes therapy in heart failure with preserved or reduced ejection fraction. JACC Heart Fail2018; 6: 1–7.
74.
SeferovicPMPaulusWJ.Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J2015; 36: 1718–1727, 1727a–1727c.
75.
SellHHabichCEckelJ.Adaptive immunity in obesity and insulin resistance. Nat Rev Endocrinol2012; 8: 709–716.
76.
WangCHWeiYH.Role of mitochondrial dysfunction and dysregulation of Ca(2+) homeostasis in the pathophysiology of insulin resistance and type 2 diabetes. J Biomed Sci2017; 24: 70.
77.
JiaGDeMarcoVGSowersJR.Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol2016; 12: 144–153.
78.
HitomiHKiyomotoHNishiyamaA, et al. Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension2007; 50: 750–755.
79.
BenderSBMcGrawAPJaffeIZ, et al. Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease?Diabetes2013; 62: 313–319.
80.
JiaGHillMASowersJR.Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res2018; 122: 624–638.
81.
American Diabetes Association Professional Practice Committee. 6. Glycemic targets: standards of medical care in diabetes-2021. Diabetes Care2021; 44: S73–S84.
